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Abstract
Patent foramen ovale (PFO) is associated with clinical conditions including cryptogenic stroke, migraine and varicose veins.
Data from studies in humans and mouse suggest that PFO and the secundum form of atrial septal defect (ASDII) exist in an
anatomical continuum of septal dysmorphogenesis with a common genetic basis. Mutations in multiple members of the
evolutionarily conserved cardiac transcription factor network, including GATA4, cause or predispose to ASDII and PFO. Here,
we assessed whether the most prevalent variant of the GATA4 gene, S377G, was significantly associated with PFO or ASD.
Our analysis of world indigenous populations showed that GATA4 S377G was largely Caucasian-specific, and so subjects
were restricted to those of Caucasian descent. To select for patients with larger PFO, we limited our analysis to those with
cryptogenic stroke in which PFO was a subsequent finding. In an initial study of Australian subjects, we observed a weak
association between GATA4 S377G and PFO/Stroke relative to Caucasian controls in whom ASD and PFO had been excluded
(OR= 2.16; p = 0.02). However, in a follow up study of German Caucasians no association was found with either PFO or ASD.
Analysis of combined Australian and German data confirmed the lack of a significant association. Thus, the common GATA4
variant S377G is likely to be relatively benign in terms of its participation in CHD and PFO/Stroke.
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Introduction
Stroke is the third leading cause of death [1] and the major
cause of serious, long-standing disability in the United States [2]
affecting about 800,000 individuals each year [3]. Among cases
with ischemic stroke, 18–42% have no identifiable cause and are
termed cryptogenic [4–7]. A well-recognised risk factor for
cryptogenic stroke, particularly in young patients, is patent
foramen ovale (PFO) [8], a common cardiac atrial septal variant
in which the septum primum fails to fuse with the septum
secundum after birth, leading to the potential for inter-atrial
communication. Approximately 50% of stroke patients younger
than 55 years have PFO [9–12], which is at least double the
prevalence in the general population [13,14]. A likely mechanism
for involvement of PFO in stroke is ‘‘paradoxical embolism’’, in
which a venous thrombus crosses the atrial septum and enters the
systemic circulation, although an abnormal septum may also be
thrombogenic [8]. The severity of PFO in the normal population
is variable, ranging from small pinhole openings to large tunnel-
shaped corridors, and only ,1% of PFO show an inter-atrial
communication of $10 mm [14]. However, PFO in patients with
stroke are generally large (.2 mm) [15,16] and often associated
with increased mobility or aneurysm of the fossa ovalis membrane,
the remnant of embryonic septum primum [17,18].
PFO is also associated with other conditions. A number of
studies show a higher prevalence of PFO in migraineurs with aura
[19,20,21] and a dramatic lessening of migraine attacks after PFO
closure [22,23], suggesting that PFO acts as a risk factor for
migraine. However, not all studies found such an association [24].
Neurological decompression sickness is also more common in
divers with PFO (and ASD) [25] and a recent study found that the
prevalence of PFO was higher in patients with symptomatic
varicose veins due to great saphenous incompetence [26].
There is no conclusive data on the underlying causes of PFO,
although there is good evidence that genetic factors are involved
[27–31]. The newly reported association between PFO and
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varicose veins [26], a common and highly hereditary vascular
abnormality [32], also indicates genetic contribution to PFO.
ASD is a more severe atrial septal abnormality than PFO [33].
In the secundum form of ASD (ASDII), there is incomplete
coverage of the fossa ovalis by the atrial septum primum, leading
to persistent shunting of blood from left to right atrium. ASDII
accounts for approximately 7% of all cases of congenital heart
defect (CHD) [34,35].
A link between ASD and PFO has not been formally established
in humans, although the largest and most complex PFO can be
difficult to distinguish from ASD and are often regarded as form
fruste ASD. This relationship is also strongly suggested by family
studies, including those bearing mutations in cardiac transcription
factor genes. Mutations in TBX20, for example, are associated
with defects in septation including ASD and PFO with permanent
left-to-right shunt [27]. Heterozygous TBX20 mutant mice show
an increased background prevalence of PFO and septal dysmor-
phogenesis, as well as a genetic predisposition to ASD [30].
Mutations in the homeodomain factor NKX2-5, a key transcrip-
tional regulator of cardiac development, cause familial ASD in
humans, and in mice lead to a high prevalence of PFO correlating
with the severe end of a spectrum of atrial septal dysmorphogen-
esis [31,36–42]. The prevalence of PFO in mice is also highly
genetic background-dependent. Collectively, these data suggest
that ASD and PFO exist in an anatomical continuum with a
common genetic basis. Furthermore, the genetic underpinnings of
PFO are likely to be highly heterogeneous. Indeed, analysis of
quantitative trait loci (QTL) contributing to atrial septal defects or
PFO in inbred strains of mice identified 13 significant or suggestive
QTL [43].
GATA4 belongs to the conserved GATA family of zinc finger
transcription factors which play an important role in mammalian
cardiac lineage specification and morphogenesis [44]. Mutations
in GATA4 are associated with CHD in humans, particularly
ASDII [45]. Thus, it is apparent that perturbations in multiple
members of the evolutionarily conserved cardiac transcription
factor network cause or predispose to ASDII and PFO. The most
prevalent variant of the GATA4 gene is an A.G non-synonymous
transition at position c.1647 resulting in a serine to glycine change
at amino acid 377 (GATA4 S377G) with a minor allele frequency
of 0.11 [46]. Although this is a conservative amino acid change,
the polymorphism is located within the C-terminal GATA4
domain which is highly conserved in vertebrate species and
essential for GATA4 transcriptional activity [45,47,48]. In vitro
functional analysis using the alpha myosin heavy chain promoter
revealed that GATA4 S377G has a significantly enhanced
transcriptional activity compared to wildtype GATA4 [49].
Although S377G showed no significant association with migraine
[50], an association with CHD including ASD and PFO has not
been characterized so far.
Here, we address whether there is a significant association
between this GATA4 variant and ASD or PFO in patients
unselected for family history. To focus on the more severe end of
the PFO spectrum, PFO subjects comprised largely patients with
cryptogenic stroke in whom PFO was subsequently found by
echocardiography.
Materials and Methods
Global distribution of S377G
The distribution of S377G allele (dbSNP ref. 3729856) was
determined in different indigenous populations [51] (Table 1)
using Fluorescence Polarisation [52].
Ethics Statement
All human experiments in the Australian study were carried out
under Human Research Ethics Committee approval from the
South East Health Research Ethics Committee – Eastern Division,
the St Vincent’s Hospital Research Ethics Committee and the
Children’s Hospital at Westmead Research Ethics Committee.
The German study protocol was approved by the Institutional
Review Board of the Charite´-Universita¨tsmedizin Berlin, Ger-
many.
Written informed consent was obtained from all participants (or
parental/legal guardian on behalf of the children participating in
the study).
Australian Study
Subjects were recruited from Sydney hospitals from 1982 to
2004 and those of Caucasian descent were selected for the study.
Adult ASD and CHD patients were recruited mostly from St.
Vincent’s Hospital and St. Vincent’s Private Hospital (SVHs),
while children were from the Sydney Children’s Hospital (SCH)
and the Children’s Hospital at Westmead (CHW). Most were
recruited prospectively during outpatient services and were
unselected for family history or particular cardiac anomalies.
PFO and Stroke patients were recruited prospectively from St
Vincent’s Hospital and St Vincent’s Private Hospital after referral
to echocardiography services for a variety of indications including
stroke or transient ischemic episode (TIA). Allocation to case (PFO
with cryptogenic stroke; n= 58) and control (PFO without stroke/
TIA, n= 29; stroke/TIA without PFO/ASD, n= 66) groups
occurred retrospectively. Cases consisted of 58 individuals under
investigation for cryptogenic stroke in whom PFO was demon-
strated by transesophageal echocardiography (TEE). In control
groups, PFO was either absent or an incidental finding, as also
determined by TEE.
Clinical evaluation included medical history, 12-lead electro-
cardiography and transthoracic echocardiography and/or TEE
with intravenous saline contrast injection during the strain and
release phases of the Valsalva maneuvre. Two additional control
groups were also assessed. TEE controls recruited from St.
Vincent’s Hospital (n = 113) had undergone TEE for a range of
indications and were reported to have structurally normal hearts,
in particular an intact atrial septum. The second group
(population controls; n = 391) were Australian Caucasians in
generally good health (no stroke or known heart disease) although
unselected for septal status [50]. The PFO/Stroke group was
restricted to patients with cryptogenic stroke. Since atrial
fibrillation (AF) is a known cause of stroke, all stroke patients
had Holter monitor evaluation unless there was prior evidence in
their medical history for AF. We excluded all patients with AF
from the PFO/Stroke group. Stroke/no PFO/ASD were also
evaluated by Holter monitor as part of their clinical evaluation,
although those with AF were included in the study.
Initially, GATA4 coding exons were amplified by polymerase
chain reaction (PCR) from 100 ng of leukocyte DNA, purified
with PCR Cleanup Plates (Millipore) and sequenced using Big Dye
Terminator v3.1 kit (Applied Biosystems) and ABI PRISMH 3700
DNA Analyser. Subsequently, GATA4 S377 status was confirmed
in all samples, including population and TEE controls, using a
commercial SNP analysis platform (Genera Biosystems). Chi-
square or the Fisher’s exact test was used to detect differences
between allele frequencies.
German study
A vast majority of individuals were of Caucasian origin and
recruited from Berlin hospitals between 2005 and 2007. There
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were three Arab patients who were included in the study since the
allele frequency of S377G is similar in both Arab and Caucasian
populations (Table 1). Ninety-six and 95 patients had isolated
ASDII and isolated PFO, respectively. ASDII probands represent
a subgroup of a previously published CHD cohort included in
genetic screening [53]. Most PFO probands (91%) had been
admitted for interventional PFO closure after experiencing one or
more thromboembolic events. All 191 cases were recruited at the
Department of Pediatric Cardiology, Deutsches Herzzentrum
Berlin, and Adult Cardiology Department at the Charite´ -
Universita¨tsmedizin Berlin, Campus Virchow (CVK).
All patients were characterized by physical examination, 12-
lead electrocardiography and TEE. Ninety-six patients attending
the Department of Cardiology CVK were used as controls after
exclusion of ASD and PFO by contrast-enhanced TEE after
Valsalva maneuvre. All ASDII and PFO patients underwent
24 hour Holter monitor. AF was found in none of the PFO
patients and all were designated as having cryptogenic stroke.
PCR fragments including the S377G variation were analysed by
single stranded conformational polymorphism (SSCP). Differential
migration patterns allowed a secure distinction of all three possible
genotypes (AA, AG, GG) on 12% Polyacrylamide gels at 20uC. All
three genotypes were confirmed in 12 samples by direct DNA
sequencing. Discrete variables were expressed as counts or percent-
ages and compared using chi-square test without Yates correction.
Fisher’s exact test was employed for association of counts of which one
subgroup was smaller than four. Continuous variables were checked
for Gaussian distribution and expressed as mean value 6 standard
deviation and were compared by use of unpaired, two sided t-test.
Results
Global distribution of GATA4 S377G
The global distribution of GATA4 S377G was determined by
analysis of DNA from world indigenous populations [51].
European, Australian, American and Middle Eastern Caucasians
had the highest allele frequency (11.3–20.2%), while Indians/
Pakistanis had a lower frequency (7.7%) (Table 1). By contrast,
Africans, East Asians and Pacific Islanders showed a very low
frequency (0–0.4%). Allele frequency for all populations was in
Hardy-Weinberg equilibrium. These data suggest a relatively
recent and Caucasian origin for S377G, potentially in a single
individual among Neolithic farming populations from the Near
East before their expansion into Europe within the last 10,000
years [54]. Further comparisons of S377G frequency were
restricted to Caucasian subjects.
Australian study
In Table 2, baseline demographics and relevant clinical data are
tabulated. As ASD and PFO likely exist in an anatomical
continuum with a common genetic basis, we also included ASD
subjects (n = 129) which were a mixture of children and adults
(mean age 21.6 yrs) and the majority had pure ASDII. Other
CHD subjects (n = 109) which served as controls, were mostly
children (mean age 3.9 yrs) and the majority had isolated
ventricular septal defect (VSD), VSD with minor abnormalities,
VSD with outflow tract defects including tetralogy of Fallot,
pulmonary atresia, transpositions or double outlet right ventricle
(DORV). Both ASD and Other CHD subjects were unselected for
family history, although 26.6% and 11%, respectively, had a
known family history of CHD.
Within PFO/stroke cases (n= 58), the mean age was 51.3 yrs,
some 12–14 yr younger than in our three adult control groups in
which septal status was known (PFO without Stroke, Stroke without
PFO/ASD, and TEE Controls), suggesting over-representation of
patients with premature stroke. No patient had severe atheroma or
AF. Only a minority (10.7%) had a family history of CHD. No
significant gender bias was evident in either cases or controls.
In all study populations, GATA4 S377G allele distribution was
in Hardy-Weinberg equilibrium. Prevalence of heterozygosity and
allele frequency varied somewhat, although not significantly,
between case and control groups (Table 3). In healthy Population
Controls, which were unselected for atrial septal status (n = 391),
the allele frequency was 12.4%, in good agreement with other
world Caucasian populations (Table 1). The frequency was not
significantly different in other CHD subjects, those with PFO
without Stroke or Stroke without PFO/ASD. However, allele
frequency in our gold standard TEE Controls who did not have
Table 1. S377G allele distribution in indigenous human populations.
Total
n
Wild type1
n (%)
S377G Heterozygosity1
n (%)
S377G Homozygosity1
n (%)
S377G Allele Frequency1
%
Caucasian Caucasian US 480 382 (79.6) 88 (18.3) 10 (2.1) 11.3
UK 42 27 (64.3) 13 (31) 2 (4.8) 20.2
Australia2 391 301 (77) 83 (21.2) 7 (1.8) 12.4
Cyprus 37 27 (73) 9 (24.3) 1 (2.7) 14.9
Russian Caucasus 112 84 (75) 26 (23.2) 2 (1.8) 13.4
Russia 47 33 (70.2) 14 (29.8) 0 (0) 14.9
Asian Yemen 89 64 (71.9) 24 (27) 1 (1.1) 14.6
India/Pakistan 111 94 (84.7) 17 (15.3) 0 (0) 7.7
Hong Kong 57 57 (100) 0 (0) 0 (0) 0
Taiwan 92 92 (100) 0 (0) 0 (0) 0
African Madagascar 117 116 (99.1) 1 (0.9) 0 (0) 0.4
Central African Republic 44 44 (100) 0 (0) 0 (0) 0
Pacific Islander Papua New Guinea 88 88 (100) 0 (0) 0 (0) 0
1Reflects the prevalence of the A.G single nucleotide polymorphism that causes the S377G amino acid change.
2The same population were used as ‘‘population controls’’ in the Australian cohort.
doi:10.1371/journal.pone.0020711.t001
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stroke and in whom ASD and PFO had been specifically excluded
(n = 113), was lower at 9.3%. Although this fell short of
significance when compared to Population Controls (p = 0.20), it
would be the expected trend if S377G played a causative role in
PFO at the severe end of the spectrum.
Allele frequency was also low in ASD subjects (9.3%), indicating
no role for S377G in causation of ASDII. The differences between
the ASD group and controls were not statistically significant.
However, an excess of S377G was observed in cases with PFO and
stroke, with an allele frequency of 18.1% (p= 0.02 comparing to
the TEE control group).
German study
We also assessed S377G allele frequency independently in
German Caucasians with ASD and PFO compared to the TEE
controls. Basic demographics and clinical information from ASD
and PFO subjects are shown in Table 4. The ASD group (n= 96)
comprised children and adults (aged 2.9 yrs to 75.9 yrs) who were
mostly female (70.5%). This female preponderance of ASD is
consistent with a previous epidemiologic report [55]. PFO
probands (n = 95) were all adults (mean age 52.9) who mostly
had been admitted subsequent to neurologic events (91.2%).
During TEE, atrial septal aneurysm (ASA) was detected in a
relatively high number of ASDs and PFOs (37.4% and 40.7%
respectively). It is known that ASA is often associated with other
atrial septal defects, in particular ASDII and PFO, and is also a
risk factor for stroke [56,57,58]. More than two thirds of ASD
subjects had an ECG pattern of right bundle branch block (RBBB)
and about 14% had atrioventricular block (AVB). In the PFO
group, RBB was found in just 20% and one patient had AVB.
In the German Caucasians, the S377G allele frequency was not
significantly different between ASDs, PFOs and TEE controls
(range 12% to 13.5%), and it was close to the allele frequency of
other world Caucasian populations (Table 5).
Pooled data
We continued recruitment of Australian Caucasians in the same
St. Vincent’s Hospital treatment population using identical
Table 2. Clinical characteristics of Australian cohort.
ASD1
(n =129)
CHD controls2
(n =109) PFO
Stroke/no PFO/
ASD5
(n =66)
TEE Controls (no PFO/
ASD/Stroke)6
(n =113)
Caucasian
Population Controls
(n =391)
With Stroke3
(n =58)
Without
Stroke4
(n =29)
Age at Study7
(yrs)
0–77
(mean:21.6)
0.1–44.3
(mean:3.9)
19–86
(mean:51.3)
38–88
(mean:65.9)
29–87
(mean:65.9)
21–89
(mean:63.3)
16–84
(mean:53.1)
Male (%) 54 (41.9) 69 (63.3) 32 (55.2) 20 (69.0) 44 (66.7) 66 (58.4) 200 (50)
Family History of
CHD
n/total (%)7
34/128 (26.6) 12/109 (11.0) 6/56 (10.7) 4/27 (14.8) 2/65 (3.1) 12/113 (10.6) N/A
Severe Atheroma
n/total (%)8
N/A N/A 0/43 (0.0) 3/29 (10.3) 18/66 (27.3) 18/109 (16.5) N/A
Atrial Fibrillation
n/total (%)
N/A N/A 0/58 (0.0) N/A 13/66 (19.7) N/A N/A
1Includes 2 APVD, 2 LSVC, 2 Coarctation of the aorta, 2 Pulmonary Stenosis, 1 LSVC & Pulmonary Stenosis, 1 PDA, 3 MVP.
2Includes 26 isolated VSD, 17 VSD with minor abnormalities, 1 functional single ventricle and 64 VSD with malformations of outflow tracts - these include 34 with
Tetralogy/pulmonary atresia, 15 with transposition/DORV and 15 with other malformations.
3Includes 1 Ebstein’s Anomaly, 2 MVP, 1 prosthetic pulmonary valve, 1 prosthetic mitral valve.
4Includes 1 Quadri-leaflet Aortic Valve, 3 MVP, 3 prosthetic AV, 1 prosthetic AV&MVR.
5Includes 1 BAV, 4 MVP, 4 prosthetic AV, 2 MVR.
6Includes 1 Ebstein’s Anomaly, 8 BAV, 1 BAV & Coarctation of the Aorta, 1 BAV & MVR, 1 Sick Sinus Syndrome, 1 PDA, 1 aortic root replacement, 9 MVP, 3 prosthetic MV,
6 prosthetic AV, 2 prosthetic AV&MV, 1 MVR, 1 prosthetic AV & MVR, 1 MVR & tricuspid VR.
7Family history was unknown for a small number of patients.
8Grade of atherosclerosis was unknown for 14 cases with PFO and stroke, 2 cases with PFO and without stroke and 4 TEE controls.
doi:10.1371/journal.pone.0020711.t002
Table 3. GATA4 genotypes of Australian cohort.
ASD
(n=129)
CHD controls
(n=109) PFO
Stroke/no
PFO/ASD
(n=66)
TEE Controls (no
PFO/ASD/Stroke)
(n =113)
Population
Controls
(n=391)
With Stroke
(n =58)
Without Stroke
(n =29)
GATA4 S377G Heterozygous (%) 18 (14) 24 (22.0) 15 (25.9) 8 (27.6) 16 (24.2) 17 (15.0) 83 (21.2)
Homozygous (%) 3 (2.3) 3 (2.8) 3 (5.2) 0 (0.0) 0 (0.0) 2 (1.8) 7 (1.8)
Allele Frequency 9.3 13.8 18.11 13.8 12.1 9.3 12.4
1p = 0.02 compared to TEE Controls; Odds ratio 2.16.
doi:10.1371/journal.pone.0020711.t003
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inclusion criteria and patient classification as in the original study,
but over two years were only able to recruit 32 new cases of PFO
with neurologic event. Among them, only 8 had undergone PFO
closure. This low number may be because of depletion of adults
with severe PFO in the treatment population. However, in the
same time frame, we collected an additional independent group of
134 TEE controls.
The power of both Australian and German studies was
weakened by the low number of subjects. Given relative
homogeneity of two studies, we pooled data from all subjects
including the additional TEE controls, into one data set for
analysis (Table 6). Subjects with PFO (n= 183) and ASD (n= 234)
showed S377G allele frequencies of 13.9% and 10.7%, respec-
tively, which were not significantly different compared to TEE
controls (n = 340, S377G allele frequency = 11.9%).
Discussion
GATA transcription factors regulate several biological processes
during embryogenesis including cardiac development. Of the six
vertebrate GATA factors, GATA4, GATA5 and GATA6 are
involved in cardiogenesis [59–62]. Several mutations in GATA4
have been previously described in patients with CHD, including
677delC and Arg283His which were reported in patients with
complex heart malformations encompassing ASD, VSD, common
atrioventricular canal, and PFO [63]. S377G is located within the
conserved and essential C-terminal GATA4 domain and leads to
an increase in transcriptional activity of GATA4 in vitro [49].
Given the causal role of GATA4 in CHD, this common allele may
play a modifier role.
We initially screened for GATA4 S377G in three different sets
of CHD patients including those with ASD, PFO and other forms
of CHD, all of Australian Caucasian origin. We observed high
allele frequency of S377G in subjects with PFO and stroke (18%)
which was significantly higher than in TEE controls in whom ASD
and PFO were excluded (p = 0.02). This finding suggested a role
for S377G in the etiology of PFO complicated by stroke. However,
several observations make this result less compelling. Around one-
fourth of Caucasians unselected for septal status would be
expected to have PFO [14]. If S377G was involved in causation
of PFO we would expect its frequency in Population Controls to
be higher than that in TEE Controls. Indeed, this was the case
(12.4% vs 9.3%). However the difference was not statistically
significant (p = 0.20). Furthermore, the difference in S377G
frequency between patients with PFO and stroke, and population
controls (18.1% vs 12.4%) was non-significant.
It is possible that an increased frequency of S377G in the
patients with PFO and stroke is due to an independent effect of
this variant on stroke risk. For example, GATA4 represses the
transcriptional activity of apolipoprotein(a) gene [64], high levels
of which are an independent risk factor for premature atheroscle-
rosis and stroke [65,66]. However, a direct association between
S377G and stroke is unlikely because the allele frequency of
S377G in the ‘‘stroke/no PFO/ASD’’ group (12.1%) was not
different from that of TEE or population controls.
There was no association between S377G and PFO complicat-
ed by cryptogenic stroke when we analysed an independent group
of German Caucasians including 95 subjects with PFO, most of
whom had experienced a neurologic event. The S377G allele
frequency was not significantly different in any comparison
between ASDs, PFOs and TEE controls. Analysis of combined
Australian and German data confirmed the lack of association.
In our initial screen of 162 subjects (including 43 PFO/stroke, 9
incidental PFO with no stroke and 110 ASD subjects), all coding
exons of the GATA4 gene were sequenced. No GATA4 variants
were identified in the PFO/stroke cohort. However, we found 4
non-synonymous variants, 3 in the ASD group (full gene deletion;
E359del; A411V) and one in an incidental PFO subject (D425N).
Table 4. Clinical characteristics1 of German cohort.
ASDII2
(n= 96)
PFO/Stroke3
(n=95)
Age at study
(yrs)
2.9–75.9
(mean:38.6)
26.3–74.4
(mean:52.9)
Male (%) 28 (29.5) 50 (54.9)
Family history of CHD
n/total (%)
8/42 (19.2) 1/58 (1.7)
Neurologic event (%)4 9 (9.9) 83 (91.2)
Migraine (%) 3 (3.3) 6 (6.6)
Defect closure (%)5 89 (98.9) 91 (100)
Atrial septal aneurysm (%) 34 (37.4) 37 (40.7)
AVB (%)6 13 (14.3) 1 (1.1)
iRSB/RSB (%)7 68 (73.9)/6 (6.5) 19 (20.0)/2 (2.1)
Atrial Fibrillation (%) 3 (3.3) 0 (0)
1Family history was unknown for 54 cases with ASDII and 37 cases with PFO.
Other Clinical characteristics were unknown for a small number of patients.
2All ASDII cases were free of any other cardiac malformation.
3All PFO cases were free of any other cardiac malformation. All were designated
as having cryptogenic stroke.
4Neurologic event includes thromboembolic stroke, PRIND (prolonged
reversible ischemic neurologic deficit) and TIA.
5Defect closure includes interventional closure and surgical closure.
6AVB: electrocardiographic atrioventricular block.
7iRSB/RSB: (incomplete) right bundle block.
doi:10.1371/journal.pone.0020711.t004
Table 5. GATA4 genotypes of German cohort.
ASDII
(n = 96)
PFO/Stroke
(n =95)
TEE Controls
(no PFO/ASD)
(n=96)
GATA4
S377G
Heterozygous
(%)
15 (15.6) 21 (22.1) 16 (16.7)
Homozygous
(%)
4 (4.2) 1 (1.1) 5 (5.2)
Allele
Frequency
12 12.1 13.5
doi:10.1371/journal.pone.0020711.t005
Table 6. Pooled genotype data from Australian and German
Cohorts.
ASDII
(n =234)
PFO/Stroke
(n=183)
TEE Controls
(no PFO/ASD)
(n =340)
GATA4
S377G
Heterozygous (%) 36 (15.4) 41 (22.4) 65 (19.1)
Homozygous (%) 7 (3) 5 (2.7) 8 (2.4)
Allele Frequency 10.7 13.9 11.9
doi:10.1371/journal.pone.0020711.t006
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These changes were not detected by subsequent screening in 270
controls. A411V and D425N have been reported in a separate
publication describing a larger screen [67]. While potentially
deleterious, there were no obvious functional consequences of
these mutations in transient transfection assays.
In summary, the study of independent and pooled populations
of Australian and German Caucasians failed to show a significant
association between S377G and PFO with stroke. We conclude
that the common GATA4 variant S377G is relatively benign in
terms of its participation in CHD and PFO/Stroke. However, it
remains possible that common mutations in other cardiac
transcription factors play a significant role in the pathogenesis of
cryptogenic stroke through causation of PFO.
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